Jardiance vs Farxiga for Diabetes, Heart and Kidney Care

Jardiance and Farxiga are prescription medicines in the same drug class, called SGLT2 inhibitors. Both can help manage type 2 diabetes and may benefit certain people with heart failure or chronic kidney disease, but the best choice depends on a person’s diagnosis, kidney function, other medicines, and treatment goals.

Jardiance vs Farxiga at a glance

Jardiance vs Farxiga is usually not a question of one medicine being universally stronger or safer than the other. Both belong to the sodium-glucose cotransporter-2 (SGLT2) inhibitor class, but doctors distinguish them by the condition being treated, the evidence and approved uses in the local country, kidney function, and the person’s overall health profile.

Feature	Jardiance	Farxiga
Generic name	Empagliflozin	Dapagliflozin
Medicine class	SGLT2 inhibitor	SGLT2 inhibitor
Main effect	Helps the kidneys pass glucose into urine; can also affect fluid balance	Helps the kidneys pass glucose into urine; can also affect fluid balance
Common clinical uses	Type 2 diabetes, heart failure, and chronic kidney disease in appropriate adults	Type 2 diabetes, heart failure, and chronic kidney disease in appropriate adults
How it is taken	Usually an oral tablet taken once daily	Usually an oral tablet taken once daily
Important shared cautions	Genital infections, dehydration, ketoacidosis, kidney-function changes, and low blood sugar when combined with certain diabetes medicines	Genital infections, dehydration, ketoacidosis, kidney-function changes, and low blood sugar when combined with certain diabetes medicines

Neither medicine replaces healthy eating, physical activity where appropriate, blood-pressure management, or routine medical follow-up. They are prescription medicines, and their exact approved indications, eligibility criteria, and kidney-function thresholds can differ by country and may change as evidence and medicine labeling are updated.

How a clinician tells Jardiance and Farxiga apart

Doctors begin by defining the main treatment goal. For a person with type 2 diabetes, the goal may be improving blood glucose alongside weight, blood-pressure, heart, and kidney considerations. For another person, the main reason for an SGLT2 inhibitor may be reducing the risk of worsening heart failure or slowing progression of chronic kidney disease, even if they do not have diabetes.

The clinician then reviews the medicine’s approved use for that particular condition, as well as clinical-trial evidence and professional guidelines. Both empagliflozin and dapagliflozin have important evidence in heart and kidney disease, but a doctor may prefer one option when it fits a specific diagnosis, prior treatment plan, formulary, or local prescribing guidance more closely.

Kidney function is a central part of the decision. These medicines work partly through the kidneys, so the estimated glomerular filtration rate (eGFR) is checked before treatment and periodically afterward. The kidney-function level at which a medicine is suitable for glucose lowering may not be the same as the level at which it can be used for heart failure or kidney protection; the prescriber uses the current product information for the individual situation.

What the choice may look like in type 2 diabetes

For adults with type 2 diabetes, both medicines can lower blood glucose by reducing the kidney’s reabsorption of glucose. More glucose then leaves the body in urine. This mechanism is different from insulin and from medicines that stimulate the pancreas to release more insulin, which is why an SGLT2 inhibitor may be combined with other diabetes treatments.

When selecting Jardiance or Farxiga for glucose management, a clinician considers the person’s current HbA1c, blood glucose pattern, kidney function, body weight, blood pressure, risk of low blood sugar, and other conditions. SGLT2 inhibitors alone do not usually cause hypoglycemia. However, low blood sugar can occur when either medicine is used together with insulin or a sulfonylurea, and the doses of those medicines may need review.

A history of cardiovascular disease may also influence the discussion. In people with type 2 diabetes, controlling glucose is important, but treatment is not based on glucose alone. The clinician may select medicines that also address established heart disease, heart-failure risk, kidney disease, or the person’s need for a simple and sustainable daily regimen.

What the choice may look like in heart or kidney disease

Heart failure is a condition in which the heart does not pump or fill as effectively as it should. SGLT2 inhibitors have become an important treatment option for many adults with heart failure, including people with reduced or preserved ejection fraction, depending on their clinical circumstances and local guidance. Their benefits in this setting are not limited to people with diabetes.

Chronic kidney disease is another common reason a specialist may consider Jardiance or Farxiga. These medicines may help protect kidney function and reduce certain heart-related risks in appropriate adults with chronic kidney disease. The decision includes the cause and stage of kidney disease, urine albumin levels when relevant, eGFR, blood pressure, and use of other kidney-protective treatments.

It is common for eGFR to show a small early change after an SGLT2 inhibitor is started. This does not automatically mean the medicine is harming the kidneys, but it should be interpreted by the prescribing clinician in context. Regular follow-up is especially important for people who use diuretics, have low blood pressure, are older, or have recently been unwell with vomiting or diarrhea.

Shared side effects and safety considerations

Because both medicines increase glucose in the urine, genital fungal infections can occur. Symptoms may include itching, redness, soreness, unusual discharge, or discomfort. Urinary tract infections can also occur, although not every urinary symptom is caused by the medicine. Good genital hygiene, prompt attention to symptoms, and discussing recurrent infections with a clinician can help.

Both medicines can increase urination and may contribute to dehydration, dizziness, or low blood pressure, particularly when fluid intake is low or when they are taken with water tablets (diuretics). A doctor may review blood-pressure medicines and diuretic treatment before or shortly after starting an SGLT2 inhibitor. People should not make medication changes on their own.

A rare but serious risk is diabetic ketoacidosis, which can sometimes occur with only mildly raised blood glucose. Nausea, vomiting, abdominal pain, unusual tiredness, rapid or deep breathing, or confusion need urgent medical assessment. These medicines are generally not used to treat type 1 diabetes, and people at risk of ketoacidosis need individualized advice about whether an SGLT2 inhibitor is appropriate.

Before surgery, a prolonged fast, or during significant illness, the prescriber may advise temporarily stopping the medicine to lower ketoacidosis and dehydration risk. This is sometimes called a sick-day or perioperative plan. Patients should ask their healthcare team for clear instructions rather than stopping or restarting Jardiance or Farxiga without guidance.

Practical steps when starting or changing treatment

A person should take Jardiance or Farxiga exactly as prescribed and should not switch between them solely because they are in the same drug class. Although their mechanisms are similar, the prescribed dose, clinical indication, monitoring plan, and insurance or local availability arrangements may differ. A switch should be planned by the clinician who understands the person’s medical history.

Before starting treatment, it is useful to share a full medication list, including insulin, sulfonylureas, diuretics, blood-pressure medicines, and non-prescription products. The clinician should also know about prior genital infections, frequent urinary infections, low blood pressure, restrictive eating, heavy alcohol use, planned surgery, pregnancy, breastfeeding, or a past episode of ketoacidosis.

Follow-up may include blood-pressure checks, kidney blood tests, glucose monitoring when diabetes is present, and a review of side effects. People with diabetes should continue their agreed glucose-monitoring routine. They should also maintain hydration as advised by their healthcare professional, while following any fluid restriction that may be needed for heart or kidney disease.

When to seek medical care

Medical advice should be sought promptly for symptoms of a genital or urinary infection, persistent dizziness, fainting, markedly reduced urination, or symptoms that suggest dehydration. Patients should also contact their clinician if blood glucose readings are persistently outside their agreed target range or if side effects make it difficult to continue the medicine.

Urgent medical care is needed for possible ketoacidosis symptoms, including nausea, vomiting, stomach pain, rapid or labored breathing, severe weakness, or confusion. Urgent assessment is also appropriate for fever or severe pain, swelling, or tenderness around the genital or perineal area, as serious infections in this region are rare but require immediate treatment.

For people considering Jardiance or Farxiga, a diabetes specialist, cardiologist, nephrologist, or primary-care clinician can help match treatment to the underlying condition. Acıbadem Health Point’s multidisciplinary specialists and JCI-accredited hospitals diagnose and treat diabetes, heart failure, and kidney disease for international patients.

Frequently asked questions